Fig. 2: Changes in biomarker concentrations are significantly associated with response to atrasentan treatment in patients from the discovery cohort. | Nature Communications

Fig. 2: Changes in biomarker concentrations are significantly associated with response to atrasentan treatment in patients from the discovery cohort.

From: Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial

Fig. 2: Changes in biomarker concentrations are significantly associated with response to atrasentan treatment in patients from the discovery cohort.

This forest plot shows the mean odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between concentration changes in four urine biomarkers, kallikrein B1 (KLKB1), α2-macroglobulin (A2M), plasminogen (PLG) and clusterin (CLU), and patient treatment response. Increased biomarker concentrations from baseline to 6 weeks post-treatment is associated with reduced likelihood of being a responder (binary classified as “R” for responder or “NR” for non-responder, n = 60 for each group). Each biomarker and its OR range are depicted by horizontal lines. A dashed line at OR = 1.0 indicates no effect. ORs to the right suggest a tendency towards non-response; to the left towards response. The ORs are computed using logistic regression adjusted for age, sex, systolic and diastolic blood pressures, estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (uACR), and hemoglobin A1c (HbA1C). Statistical significance, p < 0.05, was assessed using the Wald test. Mean changes for responders (R), non-responders (NR), and the overall mean change of all patients are included.

Back to article page